Triple-Negative Breast Cancer: A Clinicopathological Study from Rural Tertiary Care Hospital of Central India
A clinicopathological study of triple-negative breast cancer
Keywords:
Breast cancer, Triple negative, Aggressive, PrognosisAbstract
Introduction
Breast cancer is the most prevalent cancer among women in India, with higher incidence rates for aggressive molecular subtypes, like triple-negative breast cancer (TNBC).
Methods
In this single centre retrospective cohort study, we analysed 140 breast carcinoma cases (70 cases each of TNBC and non- TNBC) from June 2019 to June 2022. The clinical and morphological details taken were patients age, body mass, family history, tumor size, lymph node status, histological grade, molecular subtypes on the basis of immunohistochemical expression of ER, PR and HER2/neu status, clinical stage, recurrence, metastasis, treatment Surgery/Adjuvant chemotherapy/radiotherapy received and survival.
Results
The incidence of triple negative breast cancer is 20.21%. The median age for patients was 50.20 years with a clustering of 47.14% of cases between 40 and 59 years of age. Amongst TNBC 68.7% cases were high-grade tumours as compared to 65.71% non- TNBC tumours. Most of the patients were in stage III, with 365 (48.08%) cases. The majority of patients with TNBC belong to TNM stage III (34; 48.57%), and IV (11; 15.71%). TNBC patients had higher chances of local recurrence, distant metastasis and higher mortality as compared to non-TNBC patients (ϗ2- 4.51; p=0.03, S).
Conclusion
Triple negative breast cancer tends to occur in young women, had higher chances of local recurrence, distant metastasis and higher mortality as compared to non-TNBC patients. Amongst the molecular subtypes, TNBC is an aggressive tumor with poor survival outcome.Further, studies with larger samples and careful analysis within the same geographical areas are needed.
References
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. doi:10.3322/caac.21834
Xu, Y., Gong, M., Wang, Y. et al. Global trends and forecasts of breast cancer incidence and deaths. Sci Data 10, 334 (2023). https://doi.org/10.1038/s41597-023-02253-5
Nag, S., Dikshit, R., Desai, S. et al. Risk factors for the development of triple-negative breast cancer versus non-triple-negative breast cancer: a case–control study. Sci Rep.2023;13:3551 https://doi.org/10.1038/s41598-023-40443-8s
Kulothungan, V., Ramamoorthy, T., Sathishkumar, K. et al. Burden of female breast cancer in India: estimates of YLDs, YLLs, and DALYs at national and subnational levels based on the national cancer registry programme. Breast Cancer Res Treat.2024;205:323–332 https://doi.org/10.1007/s10549-024-07264-3
Thakur, K., Bordoloi, D., Kunnumakkara AAlarming Burden of Triple-Negative Breast Cancer in India,Clinical Breast Cancer.2018; 18(3):393-399,ISSN 1526-8209,https://doi.org/10.1016/j.clbc.2017.07.013.
McDonald, J.A., Rao, R., Gibbons, M. et al. Symposium report: breast cancer in India—trends, environmental exposures and clinical implications. Cancer Causes Control.2021;32;567–575 (2021). https://doi.org/10.1007/s10552-021-01428-y
Bajpai J, Kashyap L, Vallathol DH, Das A, Singh M, Pathak R, et al. Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort. Breast. 2022 Jun; 63:77-84.
Yavuz BB, Aktan M, Kanyilmaz G. Prognostic factors in patients with triple negative breast cancer undergoing adjuvant radiotherapy. 10-year single center experience: Triple negative breast cancer. Archives of Breast Cancer. 2022 May 15:377-85.
Fitzgibbons P.L., Dillon D.A., Alsabeh R., Berman M.A., Hayes D.F., Hicks D.G., Hughes K.S., Nofech-Mozes S. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. Arch. Pathol. Lab. Med.2014; 138:595–601. doi: 10.5858/arpa.2013-0566-CP
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25:118–45. [PubMed] [Google Scholar] [Ref list]
Reddy GM, Suresh PK, Pai RR. Clinicopathological Features of Triple Negative Breast Carcinoma. J Clin Diagn Res. 2017;11(1):EC05-EC08. doi:10.7860/JCDR/2017/21452.9187
Sarkar S, Akhtar M. Triple negative breast cancer prevalence in indian patients over a decade: a systematic review. Int J Clin Biostat Biom. 2022;8:045.
Krishnamurthy J, Kumar PS. Significance of prognostic indicators in infiltrating duct carcinoma breast: Scenario in developing country. Indian J Cancer. 2016 Jan-Mar;53(1):34-8.
Roy N, Mathew A. Triple Neagtive Breast Cancer in India: What is the Real Incidence? Ind J Med Paediatr Oncol 2023; 44:442–444.
Akhtar M, Dasgupta S, Rangwala M. Triple negative breast cancer: An Indian perspective. Breast Cancer (Dove Med Press). 2015 Aug 14; 7:239-43.
Chintalapani SR, Bala S, Konatam ML, Gundeti S, Kuruva SP, Hui M. Triple-negative breast cancer: Pattern of recurrence and survival outcomes. Indian Journal of Medical and Paediatric Oncology. 2019 Jan;40(01):67-72.
Anand AS, Joseph A, Stanley A. Pattern of recurrence in radically treated triple negative breast cancer patients. Journal of Cancer Therapy. 2021 Nov 1;12(11):611-20.
Chen HL, Ding A, Wang ML. Impact of central obesity on prognostic outcome of triple negative breast cancer in Chinese women. Springerplus. 2016; 5:594. Published 2016 May 11. doi:10.1186/s40064-016-2200-y
Nagrani, R. et al. Central obesity increases risk of breast cancer irrespective of menopausal and hormonal receptor status in women of South Asian Ethnicity. Eur. J. Cancer. 2016; 66:153–161.
Anderson K, Thompson PA, Wertheim BC, Martin L, Komenaka IK, Bondy M, et al. Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women. Springerplus. 2014 Dec 11; 3:727.
Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014 Jun;145(3):707-14.
Yin L, Shuang H, Sheng C, Liang H, Sun XJ, Yang WT, et al. The prognostic value of nodal staging in triple-negative breast cancer - a cohort from China. Sci Rep. 2018 Jun 13;8(1):9007.
Kodali D, Yi S, Zhang C, Li X, Meisel JL. The impact of obesity on triple negative breast cancer (TNBC) outcomes at a diverse academic cancer center. Journal of Clinical Oncology. 2022;40(16): e12529.
Gershuni V, Li YR, Williams AD, So A, Steel L, Carrigan E, et al. Breast cancer subtype distribution is different in normal weight, overweight, and obese women. Breast Cancer Res Treat. 2017 Jun;163(2):375-381.
He M, Zhang JX, Jiang YZ, Chen YL, Yang HY, Tang LC, et al. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer. Oncotarget. 2017 Jul 4;8(27):44870-44880.
Chandra D, Suresh P, Sinha R, Azam S, Batra U, Talwar V, et al. Eight-year survival analysis of patients with triple negative breast cancer in India. Asian Pac J Cancer Prev. 2016;17(6):2995-9.
Upadhyay AK, Prakash A. Clinicopathological Profile of Breast Cancer at a Tertiary Cancer Center in Jharkhand, India: A Descriptive Cohort Study. Cureus. 2023;15(6): e39990. Published 2023 Jun 5. doi:10.7759/cureus.39990
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Chronic Diseases Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
